Effect of melatonin and stobadine on maternal and embryofoetal toxicity in rats due to intrauterine hypoxia induced by phenytoin administration

Central European Journal of Public Health

Volumn 12, Issue SUPPL., 2004, Pages

  Ujhazy E ^a   Mach, M ^a   Dubovicky M ^a   Navarova J ^a   Soltes L ^a   Juranek I ^a   Brucknerova I ^b   Zeman, M ^c  

^a INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^b Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^c Physics and Informatics   (Slovakia)

Author keywords

Developmental toxicity; Intrauterine hypoxia; Melatonin; Phenytoin; Rat; Stobadine

Indexed keywords

ANTICONVULSIVE AGENT; ANTIOXIDANT; MELATONIN; PHENYTOIN; STOBADINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; EMBRYOTOXICITY; FEMALE; FETOTOXICITY; FETUS; FETUS DEVELOPMENT; FETUS HYPOXIA; FETUS WEIGHT; INCIDENCE; NONHUMAN; PLACENTA WEIGHT; PREGNANCY; RAT; REPRODUCTION; SKELETON MALFORMATION;

ABNORMALITIES, DRUG-INDUCED; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ANOXIA; ANTICONVULSANTS; BODY WEIGHT; CARBOLINES; FEMALE; MELATONIN; PHENYTOIN; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, WISTAR;

EID: 2342580769     PISSN: 12107778     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Sastre J, Asensi M, Rodrigo F, Pallardo, FV, Vento M, Vina J: Antioxidant administration to the mother prevents oxidative stress associated with birth in the neonatal rat. Life Sci 1994; 54(26): 2055-2059.
2. Allen RG, Balin AK: Oxidative influence on development and differentiation: an overview of a free radical theory of development. Free Radic Biol Med 1989; 6: 631-661.
3. Fantel AG: Reactive oxygen species in developmental toxicity: review and hypothesis. Teratology 1996; 53: 196-217.
4. Danielsson BR, Azarbayjani F, Skold AC, Webster WS: Initiation of phenytoin teratogenesis: pharmacologically induced embryonic bradycardia and arrhythmia resulting in hypoxia and possible free radical damage at reoxygenation. Teratology 1997; 56: 271-281.
5. Azarbayjani F, Danielsson BR: Pharmacologically induced embryonic dysrhythmia and episodes of hypoxia followed by reoxygenation: a common teratogenic mechanism for antiepileptic drugs? Teratology 1998; 57: 117-126.
6. Harbison RD, Becker BA: Diphenylhydantoin teratogenicity in rats. Toxicol Appl Pharmacol 1972; 22: 193-200.
7. Ujházy E, Dubovický M, Mach M, Juránek I, Navarová J, Sadloňová I, Gajdošik A: Effect of phenytoin on prenatal and postnatal development of rats. Biologia 2000; Suppl. 8: 125-130.
8. Huether G: The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates. Experiencia 1993; 49: 665-670.
9. Jahnke G, Marr M, Myers C, Wilson R, Travlost G, Price C: Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Tox Sci 1999; 50: 271-279.
10. Horáková L, Štolc S: Antioxidant and pharmacodynamic effects of pyridoindole stobadine: A review. Gen Pharmac 1998; 30: 789-799.
11. Balonová T, Zeljenková D, Ďurišová M, Nosál R, Jakubovský J, Líška J, Štolc S: Reproductive toxicity studies with cis(-)-2,3,4,4a,5,9-b-hexahydro-2,8-dimethyl-1H-pyrido-(4,3-b)indole dipalmitate in rats. Arzneim-Forsch 1991; 41(1): 1-5.
12. Ujházy E, Dubovický M, Balonová T. Janšák J: Teratological study of the antoxidant stobadine in rats. Gen Physiol Biophys Focus Issue 1999; 18:171-176.
13. Štolc S, Bauer V, Beneš L, Tichý M: Medicine with antiarrhythmic and antihypoxic activity and its methods of preparation. 1983, Patent ČS. 229067, SWED. 8204693-9, BELG. 894148, SWISS 651 754, BRD. P-323 1088, SPAIN 553 017, JAP. 151 4040.
14. Pizzi WJ, Jersey RM: Effects of prenatal diphenylhydantoin treatment on reproductive outcome, development, and behavior in rats. Neurotoxicol Teratol 1992; 14: 111-117.
15. Mach M, Ujházy E, Dubovický M, Navarová J, Blažček P, Šoltés L: Structural and functional changes in rat offspring induced by prenatal phenytoin administration. Med Mil Lett LXX: 2001; 79-82.
16. Gitto E, Reiter RJ, Karbownik M, Tan DX, Gitto P, Barberi S, Barberi I: Causes of oxidative stress in the pre- and perinatal period. Biol Neonate 2002; 81: 14-57.
17. Penn, JS, Talmon BL, Bullard LE: Effect of a water-soluble vitamin analog of retinopathy of prematurity. Free Rad Biol Med 1997; 22: 977-984.
18. Cedeberg J, Siman CM, Eriksson UJ: Combined treatment with vitamin E and vitamin C decreases oxidative stress and improves fetal outcome in experimental diabetic pregnancy. Pediatr Res 2001; 49: 755-762.
19. Finnel RH, Kerr BM, van Waes M, Rebecca LS, René HL: Protection from phenytoin-induced congenital malformations by coadministration of the antiepileptic drug stiripentol in a mouse model. Epilepsia 1994; 35:141-148.
20. Harblson RD, Becker BA: Effects of phenobarbital or SKF525A pretreatment on diphenylhydantoin teratogenicity in mice. J Pharmacol Exp Ther 1970; 175: 283-288.
21. Palmer AK: Incidence of sporadic malformations, anomalies and variations in random bred laboratory animals. In: Neubert D, Mecker H-J, Kwasigroch TE, eds. Methods in Prenatal Toxicology, Stuttgart, Georg Thieme Publishers 1977: 52-71.
22. Muchova S: Biochemical indicators of cell and tissue activity induced by phenytoin. PhD thesis. STU Bratislava, 2000, 1-79. (In Slovak.)